Physician profile
Deborah A Lozito
NPI 1134251945
$2,950.49
in general payments reported to CMS, 2019-2025
36 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $453 · 2021: $651 · 2022: $357 · 2023: $428 · 2024: $407 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $733.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $411.95 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $196.66 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $176.23 | 2019-2024 | |
| Allergan, INC. | $130.32 | 2020 | |
| Lilly USA, LLC | $126.92 | 2020-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $120.39 | 2019-2024 | Airsupra, Lokelma |
| Glaxosmithkline, LLC. | $117.55 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $98.69 | 2021-2023 | |
| Exact Sciences Corporation | $81.55 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.58 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $56.77 | 2019-2021 | |
| Myovant Sciences INC. | $53.59 | 2022 | |
| Genentech USA, INC. | $43.78 | 2020-2021 | |
| Amgen INC. | $42.65 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare Solutions, INC. | $42.34 | 2021 | |
| Esperion Therapeutics, INC. | $41.29 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $39.55 | 2021 | |
| Abbott Laboratories | $35.04 | 2021-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $32.14 | 2022 | |
| Sanofi Pasteur INC. | $29.45 | 2019-2023 | |
| Almatica Pharma LLC | $28.93 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.30 | 2021 | |
| Sanofi-Aventis U.S. LLC | $26.41 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $17.51 | 2023 | Contrave |
| Kowa Pharmaceuticals America, INC. | $16.76 | 2025 | Zoryve |
| Indivior INC. | $16.37 | 2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $15.81 | 2022 | |
| Lupin INC. | $14.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.88 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $14.75 | 2022 | |
| Gilead Sciences, INC. | $14.58 | 2022 | |
| Mylan Specialty L.P. | $13.98 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.75 | 2023 | Gvoke Hypopen |
| Evofem Biosciences, INC. | $13.63 | 2022 | |
| Shire North American Group INC | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Lozito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.